Abstract
Psoriasis is a chronic inflammatory skin disease caused by multiple factors. With the widespread use of biological agents, the therapeutic effect of psoriasis is gradually recognized, among which interleukin-17A (IL-17A) inhibitor has remarkable efficacy, which has aroused great attention in the academic world. However, some cases abroad have shown that IL-17A inhibitors may induce or secondary to other skin diseases in the treatment of psoriasis. In this review, we will review the case reports of other skin diseases induced or secondary to IL-17A inhibitors in the treatment of psoriasis in recent years, in order to provide a reference for clinicians in the use of this drug.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
